Search research articles
Contact Us
Filters
Showing results (91-100 of 119) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse
Laura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Future Oncology (London, England)
|
March 30, 2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies
Andrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, et al.
Clinical Epigenetics
|
October 17, 2017
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
Lia Gore, Timothy J Triche, Jason E Farrar, et al.
Haematologica
|
December 15, 2018
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG
Michael J Burke, Wanda L Salzer, Meenakshi Devidas, et al.
Leukemia Research
|
September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia
Hetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2018
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial
Lia Gore, Pamela R Kearns, Maria Lucia de Martino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2014
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies
Daniel W Bowles, Jennifer R Diamond, Elaine T Lam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2013
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer
Colin D Weekes, Daniel D Von Hoff, Alex A Adjei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
Edward S Kim, Suanna S Bruinooge, Samantha Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg, Franco Locatelli, Gerhard Zugmaier, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 119) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse
Laura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Future Oncology (London, England)
|
March 30, 2018
Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies
Andrew E Place, Kelly Goldsmith, Jean-Pierre Bourquin, et al.
Clinical Epigenetics
|
October 17, 2017
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML
Lia Gore, Timothy J Triche, Jason E Farrar, et al.
Haematologica
|
December 15, 2018
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG
Michael J Burke, Wanda L Salzer, Meenakshi Devidas, et al.
Leukemia Research
|
September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia
Hetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 3, 2018
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial
Lia Gore, Pamela R Kearns, Maria Lucia de Martino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 5, 2014
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies
Daniel W Bowles, Jennifer R Diamond, Elaine T Lam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2013
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer
Colin D Weekes, Daniel D Von Hoff, Alex A Adjei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2017
Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
Edward S Kim, Suanna S Bruinooge, Samantha Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg, Franco Locatelli, Gerhard Zugmaier, et al.
Page
of 12